93 related articles for article (PubMed ID: 20854072)
1. Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers.
Das K; Lorena PD; Ng LK; Shen L; Lim D; Siow WY; Narasimhan K; Teh M; Choolani M; Putti TC; Salto-Tellez M
Pathology; 2010; 42(6):540-6. PubMed ID: 20854072
[TBL] [Abstract][Full Text] [Related]
2. Expression patterns of Aurora A and B kinases, Ki-67 and the estrogen and progesterone receptors determined using an endometriosis tissue microarray model.
Calcagno A; Grassi T; Mariuzzi L; Marzinotto S; Londero AP; Orsaria M; Beltrami CA; Marchesoni D
Hum Reprod; 2011 Oct; 26(10):2731-41. PubMed ID: 21840910
[TBL] [Abstract][Full Text] [Related]
3. [Value of steroid hormone receptors as prognostic factors in breast, ovarian and endometrial cancer].
von Minckwitz G; Kaufmann M
Gynakologe; 1993 Apr; 26(2):100-6. PubMed ID: 8508979
[No Abstract] [Full Text] [Related]
4. Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.
Auer D; Reimer D; Porto V; Fleischer M; Roessler J; Wiedemair A; Marth C; Müller-Holzner E; Daxenbichler G; Zeimet AG
Breast Cancer Res Treat; 2009 Jul; 116(1):103-11. PubMed ID: 18618240
[TBL] [Abstract][Full Text] [Related]
5. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
6. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.
Lee P; Rosen DG; Zhu C; Silva EG; Liu J
Gynecol Oncol; 2005 Mar; 96(3):671-7. PubMed ID: 15721410
[TBL] [Abstract][Full Text] [Related]
7. Aurora kinases as prognostic biomarkers in ovarian carcinoma.
Mendiola M; Barriuso J; Mariño-Enríquez A; Redondo A; Domínguez-Cáceres A; Hernández-Cortés G; Pérez-Fernández E; Sánchez-Navarro I; Vara JA; Suárez A; Espinosa E; González-Barón M; Palacios J; Hardisson D
Hum Pathol; 2009 May; 40(5):631-8. PubMed ID: 19157502
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.
Latil A; Bièche I; Vidaud D; Lidereau R; Berthon P; Cussenot O; Vidaud M
Cancer Res; 2001 Mar; 61(5):1919-26. PubMed ID: 11280747
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 8 expression in breast carcinoma: associations with androgen receptor and prostate-specific antigen expressions.
Tanaka A; Kamiakito T; Takayashiki N; Sakurai S; Saito K
Virchows Arch; 2002 Oct; 441(4):380-4. PubMed ID: 12404063
[TBL] [Abstract][Full Text] [Related]
10. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
12. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
13. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
Nogi H; Kobayashi T; Suzuki M; Tabei I; Kawase K; Toriumi Y; Fukushima H; Uchida K
Oncol Rep; 2009 Feb; 21(2):413-7. PubMed ID: 19148516
[TBL] [Abstract][Full Text] [Related]
14. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
15. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis].
Meng J; Lang RG; Fan Y; Fu L
Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):284-8. PubMed ID: 17760256
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
18. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
20. CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival.
Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis B; Agnantis NJ
Anticancer Res; 2004; 24(3a):1665-70. PubMed ID: 15274338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
